/PRN.TO
PRN.TO Stock - Profound Medical Corp.
Healthcare|Medical - DevicesTSX
$10.03-4.11%
$0.43 (-4.11%) • Dec 22
78
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.95
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $11.03
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for PRN.TO
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$9.93 – $10.13
TARGET (TP)$11.53
STOP LOSS$9.23
RISK/REWARD1:1.9
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.22
52W High$11.45
52W Low$5.23
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $10.68M | $7.20M | $6.68M | $6.87M | $7.30M |
| Gross Profit | $7.04M | $4.38M | $3.02M | $2.95M | $3.47M |
| Gross Margin | 65.9% | 60.9% | 45.2% | 43.0% | 47.6% |
| Operating Income | $-33,062,000 | $-28,616,000 | $-29,602,000 | $-30,291,000 | $-18,863,000 |
| Net Income | $-27,816,000 | $-28,569,000 | $-28,669,000 | $-30,699,000 | $-21,622,000 |
| Net Margin | -260.4% | -396.8% | -429.1% | -446.7% | -296.0% |
| EPS | $-1.12 | $-1.35 | $-1.38 | $-1.50 | $-1.25 |
Company Overview
Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops magnetic resonance guided ablation procedures for treatment of prostate disease, uterine fibroids, and palliative pain treatment in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system used for magnetic resonance imaging scanner in hospitals and treatment facilities. The company also offers Sonalleve, a therapeutic platform for the treatment of uterine fibroids and palliative pain relief associated with metastases in bone, as well as non-invasive treatment of uterine fibroids. Profound Medical Corp. is headquartered in Mississauga, Canada.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
PRN.TOBeat Rate
56%
Last 18 quarters
Avg Surprise
-0.6%
EPS vs Estimate
Beats / Misses
10/7
1 met exactly
Latest EPS
$-0.37
Q4 2025
EPS Surprise History
Q1 24
-31.2%
$-0.42vs$-0.32
Q2 24
+7.1%
$-0.26vs$-0.28
Q3 24
+3.4%
$-0.28vs$-0.29
Q4 24
-31.0%
$-0.38vs$-0.29
Q1 25
+52.4%
$-0.20vs$-0.42
Q2 25
-28.6%
$-0.36vs$-0.28
Q3 25
+5.5%
$-0.52vs$-0.55
Q4 25
+5.7%
$-0.37vs$-0.39
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 6, 2026 | — | — | — | — |
Q1 2026 | Mar 4, 2026 | — | — | — | — |
Q4 2025 | Nov 13, 2025 | $-0.39 | $-0.37 | +5.7% | ✓ BEAT |
Q3 2025 | Aug 14, 2025 | $-0.55 | $-0.52 | +5.5% | ✓ BEAT |
Q2 2025 | May 7, 2025 | $-0.28 | $-0.36 | -28.6% | ✗ MISS |
Q1 2025 | Mar 5, 2025 | $-0.42 | $-0.20 | +52.4% | ✓ BEAT |
Q4 2024 | Nov 7, 2024 | $-0.29 | $-0.38 | -31.0% | ✗ MISS |
Q3 2024 | Aug 8, 2024 | $-0.29 | $-0.28 | +3.4% | ✓ BEAT |
Q2 2024 | May 9, 2024 | $-0.28 | $-0.26 | +7.1% | ✓ BEAT |
Q1 2024 | Mar 7, 2024 | $-0.32 | $-0.42 | -31.2% | ✗ MISS |
Q4 2023 | Nov 2, 2023 | $-0.34 | $-0.26 | +23.5% | ✓ BEAT |
Q3 2023 | Aug 9, 2023 | $-0.35 | $-0.35 | 0.0% | = MET |
Q2 2023 | May 10, 2023 | $-0.36 | $-0.32 | +11.1% | ✓ BEAT |
Q1 2023 | Mar 7, 2023 | $-0.37 | $-0.46 | -24.3% | ✗ MISS |
Q4 2022 | Nov 3, 2022 | $-0.37 | $-0.24 | +35.1% | ✓ BEAT |
Q3 2022 | Aug 4, 2022 | $-0.39 | $-0.28 | +28.2% | ✓ BEAT |
Q2 2022 | May 9, 2022 | $-0.46 | $-0.40 | +13.0% | ✓ BEAT |
Q1 2022 | Mar 3, 2022 | $-0.33 | $-0.49 | -48.5% | ✗ MISS |
Q4 2021 | Nov 4, 2021 | $-0.26 | $-0.29 | -11.5% | ✗ MISS |
Q3 2021 | Aug 4, 2021 | $-0.29 | $-0.35 | -20.7% | ✗ MISS |
Latest News
Loading news...
Frequently Asked Questions about PRN.TO
What is PRN.TO's current stock price?
Profound Medical Corp. (PRN.TO) is currently trading at $10.03 per share. The stock has moved -4.11% today.
What is the analyst price target for PRN.TO?
No analyst price targets are currently available for this stock.
What sector is Profound Medical Corp. in?
Profound Medical Corp. operates in the Healthcare sector, specifically within the Medical - Devices industry. The company is traded on the TSX exchange.
What is PRN.TO's market cap?
Profound Medical Corp. has a market capitalization of $0.30 billion, making it a small-cap company.
Does PRN.TO pay dividends?
No, Profound Medical Corp. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorCRRX.TO
CareRx Corporation
$3.87
Mkt Cap: $0.2B
CYBN.NE
Cybin Inc.
$9.79
Mkt Cap: $0.2B
DR.TO
Medical Facilities Corporation
$15.48
Mkt Cap: $0.3B
EPRX.TO
Eupraxia Pharmaceuticals Inc.
$9.70
Mkt Cap: $0.3B
HLS.TO
HLS Therapeutics Inc.
$4.75
Mkt Cap: $0.1B
JUSH.CN
Jushi Holdings Inc.
$0.76
Mkt Cap: $0.1B
NGEN.V
NervGen Pharma Corp.
$6.85
Mkt Cap: $0.5B
QIPT.TO
Quipt Home Medical Corp.
$4.84
Mkt Cap: $0.2B
VPT.V
VentriPoint Diagnostics Ltd.
$0.13
Mkt Cap: $0.0B
XLY.TO
Auxly Cannabis Group Inc.
$0.15
Mkt Cap: $0.2B
Explore stocks similar to PRN.TO for comparison